Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development

Serina Therapeutics, Inc.

SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).
U.S. TD market reached $3.7B in 2024; projected to grow to $5.4B by 2030.
Fewer than 30% of U.S. TD patients are diagnosed; less than half receive treatment.
Serina plans to explore POZ-VMAT2i for Huntington's chorea as a secondary indication.
CEO Steve Ledger to present at BTIG Virtual Biotechnology Conference on July 29, 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.